A $270 million contract running to 2031
The new agreement expands a 2020 contract between Regeneron and BARDA, an agency of the US Department of Health and Human Services responsible for preparing for health threats. Key points:
- Regeneron will supply doses of Inmazeb to the United States through 2031.
- The deal is worth about $270 million in total.
- The US Food and Drug Administration (FDA) approved Inmazeb in 2020 to treat infection caused by Zaire ebolavirus.
- The company is testing maftivimab as a potential treatment for the Bundibugyo virus.
A treatment gap against the Bundibugyo strain
The biggest challenge of this outbreak lies in the virus strain itself. The medical advances of the past decade, from vaccines to monoclonal antibody therapies such as Inmazeb, were all developed for the Zaire strain, the most common type. Against Bundibugyo, health workers are almost starting from scratch.

















